Health
Ultragenyx announces Phase 3 trial failure for Angelman syndrome therapy GTX-102
The experimental treatment showed no benefit over a sham control, marking a major setback for the company and rare disease advocates.
The short version
- Biotech firm Ultragenyx announced that its experimental drug GTX-102 failed to demonstrate clinical benefit compared to a sham control in a Phase 3 study.
- The treatment was intended for Angelman syndrome, a rare neurological condition characterized by severe intellectual disabilities and developmental delays.
- The trial outcome impacts patients and patient advocates who anticipated positive results following earlier trials, as well as investors who viewed the drug as key to the company's financial growth.
- Ultragenyx has not yet specified the next steps for the clinical development program.
Key facts
- Ultragenyx reported that its experimental drug GTX-102 failed a large Phase 3 trial after demonstrating no benefit compared to a sham treatment.[STAT]
- Angelman syndrome is a rare disorder that causes severe intellectual and developmental delays.[STAT]
- The Phase 3 outcome follows earlier clinical trials in which GTX-102 had demonstrated positive preliminary results.[STAT]
- Investors had previously viewed GTX-102 as a primary path toward profitability for Ultragenyx, which currently sells treatments primarily for ultra-rare conditions.[STAT]
What remains uncertain
- The future direction of the GTX-102 program and whether Ultragenyx will continue development in specific subgroups or terminate the candidate entirely remains unannounced.[STAT]